Introducing new products provides a key opportunity to not only expand the range of contraceptive options for women and adolescent girls, but also to strengthen family planning delivery systems for all methods.
The Contraceptive Technology Innovation (CTI) Exchange is a platform for increasing global access to resources on contraceptive research, development, registration, and introduction through collaboration and knowledge sharing. The site features Calliope, the Contraceptive Pipeline Database, which provides information on new and future contraceptive products, including long-acting and novel products currently only available in limited markets.
This brief lists key references and resources from the evidence base on DMPA-SC. Pair this with the Evidence at-a-glance brief if your target decision-maker would like to have access to the data in that handout.
This brief offers quick facts on the benefits of DMPA-SC; the product’s potential for empowering women and adolescent girls; the product’s availability; and how subcutaneous DMPA is different from intramuscular DMPA (DMPA-IM).
Subcutaneous DMPA (DMPA-SC) is an innovative and easy-to-use injectable that is transforming contraceptive access, use, and choice for women and adolescent girls. Advocates have an important role to play in making sure their country’s policies and funding support access to a broad method mix, including new options like DMPA-SC.
The Advocacy Pack for Subcutaneous DMPA is designed to accelerate your advocacy efforts. It consists of evidence-based materials, in English and French, for advocates to use both for their own strategy development and for direct advocacy with decision-makers. Materials are customizable and unbranded so that you can tailor them to your country context.
Along with the World Health Organization (WHO) Medical eligibility criteria for contraceptive use, this is one of two evidence-based guidance documents of the WHO’s initiative to develop and implement family planning guidelines for national programs. This document provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. Safety considerations include common barriers to safe, correct and consistent use of contraception and the benefits of preventing unintended or unwanted pregnancy.
Along with the World Health Organization (WHO) Selected practice recommendations for contraceptive use this is one of two evidence-based guidance documents of the WHO’s initiative to develop and implement family planning guidelines for national programs. This publication provides guidance to national family planning and reproductive health programs in the preparation of guidelines for the delivery of contraceptive services. The guide provides information on the safety and use of intramuscular and subcutaneous DMPA.
This brief outlines existing evidence on DMPA-SC with data grouped into top-line, evidence-based messages, with corresponding data from different countries. This handout can be printed and distributed directly to decision-makers. It contains several one-page spotlight handouts on specific sub-topics, which can be printed and paired with the two-page summary—for distribution to decision-makers—as needed.
This brief offers concise, evidence-based information to help answer common questions and dispel myths about injectable contraception. Myths are not stated directly because repeating a myth may reinforce it in people’s minds.